389 Shares in Chemed Co. (NYSE:CHE) Bought by Calton & Associates Inc.

Calton & Associates Inc. acquired a new position in Chemed Co. (NYSE:CHEFree Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 389 shares of the company’s stock, valued at approximately $227,000.

Several other institutional investors have also added to or reduced their stakes in CHE. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Chemed by 3.4% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 534,123 shares of the company’s stock worth $277,584,000 after purchasing an additional 17,487 shares during the period. Wellington Management Group LLP lifted its holdings in Chemed by 0.3% in the third quarter. Wellington Management Group LLP now owns 386,237 shares of the company’s stock valued at $200,727,000 after buying an additional 1,044 shares during the period. Impax Asset Management Group plc boosted its position in Chemed by 4.2% during the third quarter. Impax Asset Management Group plc now owns 311,191 shares of the company’s stock valued at $161,726,000 after acquiring an additional 12,608 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Chemed by 9.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 287,386 shares of the company’s stock worth $149,355,000 after acquiring an additional 24,161 shares during the period. Finally, Vaughan Nelson Investment Management L.P. raised its position in shares of Chemed by 2.2% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 228,040 shares of the company’s stock worth $118,513,000 after acquiring an additional 4,802 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the transaction, the executive vice president now owns 20,760 shares of the company’s stock, valued at $13,320,654. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, VP Brian C. Judkins sold 11,158 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total value of $7,196,910.00. Following the completion of the transaction, the vice president now directly owns 1,422 shares of the company’s stock, valued at $917,190. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now owns 20,760 shares in the company, valued at $13,320,654. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,808 shares of company stock valued at $10,184,531. Corporate insiders own 3.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CHE. Royal Bank of Canada upped their target price on Chemed from $604.00 to $712.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Oppenheimer raised their price objective on shares of Chemed from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Finally, StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th.

View Our Latest Research Report on CHE

Chemed Stock Performance

Shares of NYSE CHE traded up $1.11 during midday trading on Friday, hitting $575.24. 123,051 shares of the stock traded hands, compared to its average volume of 92,378. Chemed Co. has a one year low of $492.84 and a one year high of $654.62. The business has a 50 day moving average price of $616.86 and a two-hundred day moving average price of $594.70. The company has a market cap of $8.71 billion, a PE ratio of 30.96, a P/E/G ratio of 2.34 and a beta of 0.46.

Chemed (NYSE:CHEGet Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The company reported $4.68 EPS for the quarter, missing analysts’ consensus estimates of $5.09 by ($0.41). Chemed had a net margin of 12.36% and a return on equity of 30.52%. The business had revenue of $589.23 million for the quarter, compared to the consensus estimate of $587.18 million. As a group, equities research analysts forecast that Chemed Co. will post 21.72 EPS for the current fiscal year.

Chemed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Monday, February 26th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.60 dividend on an annualized basis and a yield of 0.28%. Chemed’s dividend payout ratio (DPR) is currently 8.61%.

Chemed Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.